Ukr.Biochem.J. 2014; Volume 86, Issue 5, Sep-Oct, pp. 95-101

doi: https://doi.org/10.15407/ubj86.05.095

Proteolytic activity of IgGs from blood serum of wistar rats at experimental rheumatoid arthritis

26.06.2015   Uncategorized   No comments

Yu. Ya. Kit1, S. L. Myronovsky3, I. I. Kril’2,
A. M. Havrylyuk2, V. V. Chop’yak2, R. S. Stoika1

1Institute of Cell Biology, National Academy of Sciences of Ukraine, Lviv;
2Danylo Halytsky Lviv National Medical University, Ukraine;
3Ivan Franko National University of Lviv, Ukraine;
e-mail: kit@cellbiol.lviv.ua

The aim of this work was to study the proteolytic activity of IgGs purified from blood serum of Wistar rats at experimental rheumatoid arthritis (ERA) induced by an injection of bovine collagen of type II. Twenty rats were immunized with a preparation of bovine collagen II (Sigma-Aldrich, USA) in the presence of complete Freund’s adjuvant. ERA development was determined by inflammation in limbs of treated animals. IgG preparations were isolated from blood serum of immunized and non-immunized animals by precipitation of antibodies with 33% ammonium sulfate followed by chromatography on the Protein G-Sepharose column. Human histone H1, bovine collagen II, calf thymus histones, myelin basic protein (MBP), bovine serum albumin (BSA), and bovine casein were used as substrates of the proteolytic activity of IgGs. It was found that IgG preparations from blood serum of rats with ERA were capable of cleaving histone H1 and MBP, however, they were catalytically inactive towards collagen II, casein, BSA, and core histones. IgGs from blood serum of non-immunized rats were proteolytically inactive towards all used protein substrates. Thus, we demonstrated that immunization of rats with bovine collagen II induced IgG-antibodies possessing the proteolytic activity towards histone H1 and MBP. This activity might be associated with the development of inflammatory processes in the immunized rats.

Keywords: , , , , , ,

References:

  1. Gabibov AG, Ponomarenko NA, Tretyak EB, Paltsev MA, Suchkov SV. Catalytic autoantibodies in clinical autoimmunity and modern medicine. Autoimmun Rev. 2006 May;5(5):324-30. Review. PubMed, CrossRef
  2. Belogurov A Jr, Kozyr A, Ponomarenko N, Gabibov A. Catalytic antibodies: balancing between Dr. Jekyll and Mr. Hyde. Bioessays. 2009 Nov;31(11):1161-71. Review. PubMed, CrossRef
  3. Planque S, Nishiyama Y, Taguchi H, Salas M, Hanson C, Paul S. Catalytic antibodies to HIV: physiological role and potential clinical utility. Autoimmun Rev. 2008 Jun;7(6):473-9. Review. PubMed, PubMedCentral, CrossRef
  4. Wootla B, Lacroix-Desmazes S, Warrington AE, Bieber AJ, Kaveri SV, Rodriguez M. Autoantibodies with enzymatic properties in human autoimmune diseases. J Autoimmun. 2011 Sep;37(2):144-50. Review. PubMed, PubMedCentral, CrossRef
  5. Paul S, Nishiyama Y, Planque S, Taguchi H. Theory of proteolytic antibody occurrence. Immunol Lett. 2006 Feb 28;103(1):8-16. Review. PubMed, CrossRef
  6. Li L, Paul S, Tyutyulkova S, Kazatchkine MD, Kaveri S. Catalytic activity of anti-thyroglobulin antibodies. J Immunol. 1995 Apr 1;154(7):3328-32. PubMed
  7. Ponomarenko NA, Durova OM, Voro­biev II, Aleksandrova ES, Telegin GB, Chamborant OG, Sidorik LL, Suchkov SV, Alekberova ZS, Gnuchev NV, Gabibov AG. Catalytic antibodies in clinical and experimental pathology: human and mouse models. J Immunol Methods. 2002 Nov 1;269(1-2):197-211. PubMed,  CrossRef
  8. Ponomarenko NA, Durova OM., Voro­biev II, Belogurov AA Jr, Kurkova IN, Petrenko AG, Telegin GB, Suchkov SV, Kiselev SL, Lagarkova MA, Govorun VM, Serebryakova MV, Avalle B, Tornatore P, Karavanov A, Morse HC 3rd, Thomas D, Friboulet A, Gabibov AG. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci US . 2006 Jan 10;103(2):281-6. PubMed, PubMedCentral, CrossRef
  9. Lacroix-Desmazes S, Wootla B, Delignat S, Dasgupta S, Nagaraja V, Kazatchkine MD, Kaveri SV. Pathophysiology of catalytic antibodies. Immunol Lett. 2006 Feb 28;103(1):3-7. Review. PubMed, CrossRef
  10. Paul S, Nishiyama Y, Planque S, Taguchi H. Theory of proteolytic antibody occurrence. Immunol Lett. 2006 Feb 28;103(1):8-16. Review. PubMed, CrossRef
  11. Magorivska I, Bilyy R, Shalay O, Loginsky V, Kit Y, Stoika R. Blood serum immunoglobulins of patients with multiple myeloma are capable of hydrolysing histone H1. Exp Oncol. 2009 Jun;31(2):97-101. PubMed
  12. Paul S, Nishiyama Y, Planque S, Karle S, Taguchi H, Hanson C, Weksler ME. Antibodies as defensive enzymes. Springer Semin. Immun. 2005 Jan;26(4):485-503. CrossRef
  13. Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, Paul S. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun Rev. 2008 May;7(5):391-7. Review. PubMed, PubMedCentral, CrossRef
  14. Paul S, Planque S, Nishiyama Y. Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide. J Clin Immunol. 2010 May;30 Suppl 1:S43-9. Review. PubMed, PubMedCentral, CrossRef
  15. Kit YY, Starykovych MA, Richter VA, Stoika RS. Detection and characterization of IgG- and sIgA-Abzymes capable of hydrolyzing histone H1. Biochemistry (Mosc). 2008 Aug;73(8):950-6. PubMed, CrossRef
  16. Kit YuYa, Magorivska IB, Havryliuk AM, Chop’iak VV, Bilyy RO, Stoĭka RS. Proteolytic activity of IgG of blood serum of patients with systemic lupus erythematosis. Ukr Biokhim Zhurn. 2009 May-Jun;81(3):77-83. (In Ukrainian).  PubMed
  17. Magorivska IB, Bilyy RO, Havrylyuk AM, Chop’yak VV, Stoika RS, Kit YY. Anti-histone H1 IgGs from blood serum of systemic lupus erythematosus patients are capable of hydrolyzing histone H1 and myelin basic protein. J Mol Recognit. 2010 Sep-Oct;23(5):495-502. PubMed, CrossRef
  18. Kit Yu, Starykovych M, Mahorivska I, et al. Novel Serine-Protease Like Catalytic Antibodies with Double Substrate Proteolytic Activity in Human Blood Serum and Colostrums. In. “Serine Proteases: Mechanism, Structure and Evolution”. Eds.: Isamu Chiba and Takao Kamio. Nova Sci. Publ., Inc., Hauppauge – NY. 2012:71-89.
  19. Chopyak V, Tolstiak Y, Magoryvska I, Bilyy R, Korniy N, Kit Y, Stoika R. Histone h1. MBP hydrolysing antibodies – novel potential marker in diagnosis of disease severity in systematic lupus erythematosus patients. Health. 2010;2(10):1204-1207. CrossRef
  20. Kit Y, Magorivska I, Chopyak V, Tolstiak Y, Bilyy R, Stoika R. Novel Biological Activities of Autoantibodies as the Potential Markers of Systemic Lupus Erythematosus. In “Systemic Lupus Erythematosus (SLE): Prevalence, Pathophysiology and Prognosis”. Eds.: Syuichi Koarada. Nova Sci. Publ., Inc., Hauppauge – NY. 2013:101-110.
  21. Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol. 2010 May;6(5):280-9. Review. PubMed, CrossRef
  22. Kakimoto K, Hirofuji T, Koga T. Specificity of anti-type II collagen antibody response in rats. Clin Exp Immunol. 1984 Jul;57(1):57-62. PubMed, PubMedCentral
  23. Leonavičienė L, Bradūnaitė R, Vaitkienė D, Vasiliauskas A, Keturkienė. Anti-inflammatory activity of some potassium salts of N,N-disubstituted 4-aminoazobenzenesulfonic acids in rat adjuvant arthritis. Biologiya. 2008;54(4):290-300.
  24. Bendele AM. Animal models of osteoarthritis. J Musculoskelet Neuronal Interact. 2001 Jun;1(4):363-76. PubMed
  25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680-5. PubMed, CrossRef
  26. Sun XY, Shi J, Han L, Su Y, Li ZG. Anti-histones antibodies in systemic lupus erythematosus: prevalence and frequency in neuropsychiatric lupus. J Clin Lab Anal. 2008;22(4):271-7. PubMed, CrossRef
  27. Kamalanathan AS, Goulvestre C, Weill B, Vijayalakshmi MA. Proteolysis activity of IgM antibodies from rheumatoid arthritis patients’ sera: evidence of atypical catalytic site. J Mol Recognit. 2010 Nov-Dec;23(6):577-82. PubMed, CrossRef
  28. Lacroix-Desmazes S, Bayry J, Kaveri SV, Hayon-Sonsino D, Thorenoor N, Charpentier J, Luyt CE, Mira JP, Nagaraja V, Kazatchkine MD, Dhainaut JF, Mallet VO. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci USA. 2005 Mar 15;102(11):4109-13. PubMed, PubMedCentral, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.